$VERU News
Last published 2d ago
- 2d agoVERUVeru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026GlobeNewswireMIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology,
- 2d agoVERUVeru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026GlobeNewswireMIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief Scientific Officer, Dr. Gary Barnette, will deliver a podium presentation at ObesityWeek 2026, taking place November 14-17, 2026, in Washington DC. Results ...
- 2mo agoVERUVeru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical TrialGlobeNewswire--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a
- 2mo agoVERUVeru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare ConferenceGlobeNewswireMIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 3mo agoVERUCG 46TH ANNUAL GROWTH CONFERENCE - VERU INCEarnings Call TranscriptsHi, good afternoon, everyone. Thank you for joining us. My name is Edward Nash. I'm Senior Biotech Analyst here at Canaccord Genuity in the Equity Research Department. I have the pleasure of having Mitch Steiner with me
- 3mo agoVERUCG 46TH ANNUAL GROWTH CONFERENCE - VERU INCEarnings Call TranscriptsHi, good afternoon, everyone. Thank you for joining us. My name is Edward Nash. I'm Senior Biotech Analyst here at Canaccord Genuity in the Equity Research Department. I have the pleasure of having Mitch Steiner with me
- 3mo agoVERUFiscal Year 2026 Q3 Earnings Conference Call - VERU INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to VARU ANC's Investors Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the sta
- 3mo agoVERUVeru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial ProgressGlobeNewswire-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track
- 3mo agoVERUVeru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight LossGlobeNewswire-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending
- 3mo agoVERUVeru to Report Fiscal 2026 Third Quarter Financial Results on August 10thGlobeNewswireMIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 3mo agoVERUVeru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors ConferenceGlobeNewswireMIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 3mo agoVERUVeru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight LossGlobeNewswire-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU),
- 4mo agoVERUVeru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop DayGlobeNewswireMIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 6mo agoVERUFiscal Year 2026 Q2 Earnings Conference Call - Veru IncEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to Veru, Inc.'s Investors Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the
- 6mo agoVERUVeru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial ProgressGlobeNewswire--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027— --Company to host conference call and webcast today at 8:00
- 6mo agoVERUVeru to Report Fiscal 2026 Second Quarter Financial Results on May 13thGlobeNewswireMIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 8mo agoVERUVeru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight LossGlobeNewswire-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity
- 8mo agoVERUVeru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireMIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 9mo agoVERUVeru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program ProgressGlobeNewswire-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m.
- 9mo agoVERUVeru to Report Fiscal 2026 First Quarter Financial Results on February 11thGlobeNewswireMIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 10mo agoVERUVeru Reports Fiscal Year 2025 Financial Results and Clinical Program ProgressGlobeNewswire-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable
- 11mo agoVERUVeru to Report Fiscal Year 2025 Financial Results on December 17thGlobeNewswireMIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 11mo agoVERUVeru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory WorkshopGlobeNewswireMIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru to Present Two Abstracts at ObesityWeek 2025GlobeNewswireMIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru Announces Pricing of $25 Million Public OfferingGlobeNewswireMIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru Announces Proposed Public OfferingGlobeNewswireMIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of ObesityGlobeNewswireMIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru Inc. (VERU) Q3 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoVERUVeru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program ProgressGlobeNewswire--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to
- 1y agoVERULaxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-TechnologyBusiness WireLaxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ:VERU), a late clinical-stage biopharmaceutical
- 1y agoVERUVeru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical StudyGlobeNewswireMIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru Announces Reverse Stock SplitGlobeNewswireMIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru to Report Fiscal 2025 Third Quarter Financial Results on August 12thGlobeNewswireMIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru to Participate in the 2025 BTIG Virtual Biotech ConferenceGlobeNewswireMIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru to Participate in the Virtual BTIG Obesity Health ForumGlobeNewswireMIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide AloneGlobeNewswire--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and
- 1y agoVERUJTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next LevelACCESS NewswireModerated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN, NJ /
- 1y agoVERUVeru Participates in a Virtual Investor KOL Connect SegmentGlobeNewswire-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc.
- 1y agoVERUVeru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program ProgressGlobeNewswire--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of
- 1y agoVERUVeru to Report Fiscal 2025 Second Quarter Financial Results on May 8GlobeNewswireMIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru to Present at the 2nd Annual GLP-1-Based Therapeutics SummitGlobeNewswireMIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation ConferenceGlobeNewswireMIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
- 1y agoVERUVeru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program ProgressGlobeNewswire--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and
- 1y agoVERUVeru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025GlobeNewswireMIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss,
- 1y agoVERUVeru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireMIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss,
- 1y agoVERUVeru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight ReductionGlobeNewswire-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less
- 1y agoVERUVeru Announces the Sale of the FC2 Female Condom® (Internal Condom) BusinessGlobeNewswireMIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss,
- 1y agoVERUVeru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting DisordersGlobeNewswireMIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss,
- 2y agoVERUVeru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeekGlobeNewswireMIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss,
- 2y agoVERUVeru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight LossGlobeNewswireMIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss,